Cited by 668Pregnancy and preeclampsia studiesNeurological Complications and SyndromesNeonatal and fetal brain pathology

The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.

Angiogenic Factors and the Risk of Adverse Outcomes in Women With Suspected Preeclampsia

Open access

Rana, Sarosh, Powe, Camille E., Salahuddin, Saira, Verlohren, Stefan, Perschel, Frank H., Levine, Richard J., Lim, Kee-Hak, Wenger, Julia B., Thadhani, Ravi, Karumanchi, S. Ananth·2012·Circulation

DOI 10.1161/circulationaha.111.054361PMC PMC3319742

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: An imbalance in circulating angiogenic factors plays a central role in the pathogenesis of preeclampsia. METHODS AND RESULTS: We prospectively studied 616 women who were evaluated for suspected preeclampsia. We measured plasma levels of antiangiogenic soluble fms-like tyrosine kinase 1 (sFlt1) and proangiogenic placental growth factor (PlGF) at presentation and examined for an association between the sFlt1/PlGF ratio and subsequent adverse maternal and perinatal outcomes within 2 weeks. The median sFlt1/PlGF ratio at presentation was elevated in participants who experienced any adverse outcome compared with those who did not (47.0 [25th-75th percentile, 15.5-112.2] versus 10.8 [25th-75th percentile, 4.1-28.6]; P<0.0001). Among those presenting at <34 weeks (n=167), the results were more striking (226.6 [25th-75th percentile, 50.4-547.3] versus 4.5 [25th-75th percentile, 2.0-13.5]; P<0.0001), and the risk was markedly elevated when the highest sFlt1/PlGF ratio tertile was compared with the lowest (odds ratio, 47.8; 95% confidence interval, 14.6-156.6). Among participants presenting at <34 weeks, the addition of sFlt1/PlGF ratio to hypertension and proteinuria significantly improved the prediction for subsequent adverse outcomes (area under the curve, 0.93 for hypertension, proteinuria, and sFlt1/PlGF versus 0.84 for hypertension and proteinuria alone; P=0.001). Delivery occurred within 2 weeks of presentation in 86.0% of women with an sFlt1/PlGF ratio ≥85 compared with 15.8% of women with an sFlt1/PlGF ratio <85 (hazard ratio, 15.2; 95% confidence interval, 8.0-28.7). CONCLUSIONS: In women with suspected preeclampsia presenting at <34 weeks, circulating sFlt1/PlGF ratio predicts adverse outcomes occurring within 2 weeks. The accuracy of this test is substantially better than that of current approaches and may be useful in risk stratification and management. Additional studies are warranted to validate these findings.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1161/circulationaha.111.054361

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Comparing the Areas under Two or More Correlated Receiver Operating Characteristic Curves: A Nonparametric Approach
DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia
Maynard, S. E., Min, J.-Y., Merchan, J., Lim, K.-H., Li, J., Mondal, S., Libermann, T. A., Morgan, J. P., Sellke, F. W., Stillman, I. E., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17189 · Cited by 4,101
Self-citation
Circulating angiogenic factors and the risk of preeclampsia
Levine, R. J., Maynard, S. E., Qian, C., Lim, K.-H., England, L. J., Yu, K. F., Schisterman, E. F., Thadhani, R., Sachs, B. P., Epstein, F. H., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031884 · Cited by 3,720
Self-citation
Circulating angiogenic factors and the risk of preeclampsia*
(2004) · Obstetrics and Gynecology · doi:10.1097/00006250-200405000-00028 · Cited by 2,623
Soluble Endoglin and Other Circulating Antiangiogenic Factors in Preeclampsia
Levine, R. J., Lam, C., Qian, C., Yu, K. F., Maynard, S. E., Sachs, B. P., Sibai, B. M., Epstein, F. H., Romero, R. J., Thadhani, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055352 · Cited by 1,823
Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor.
Kendall, R. L., & Thomas, K. A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.22.10705 · Cited by 1,419
Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases
Eremina, V., Sood, M. M., Haigh, J. J., Nagy, A., Lajoie, G., Ferrara, N., Gerber, H. P., Kikkawa, Y., Miner, J. H., & Quaggin, S. E. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17423 · Cited by 1,308
Soluble Endoglin and Other Circulating Antiangiogenic Factors in Preeclampsia
(2006) · New England Journal of Medicine · doi:10.1056/nejmx060063 · Cited by 1,237
ACOG Practice Bulletin No. 33: Diagnosis and Management of Preeclampsia and Eclampsia
ACOG Committee on Obstetric Practice (2002) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(01)01747-1 · Cited by 1,180
Secular Trends in the Rates of Preeclampsia, Eclampsia, and Gestational Hypertension, United States, 1987-2004
Wallis, A. B., Saftlas, A. F., Hsia, J., & Atrash, H. K. (2008) · American Journal of Hypertension · doi:10.1038/ajh.2008.20 · Cited by 759
Preterm premature rupture of the membranes
Mercer, B. (2003) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(02)02366-9 · Cited by 742
A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate
Romero, R. J., Nien, J. K., Espinoza, J., Todem, D., Fu, W., Chung, H., Kusanovic, J. P., Gotsch, F., Erez, O., Mazaki‐Tovi, S., et al. (2008) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767050701830480 · Cited by 683
Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model
von Dadelszen, P., Payne, B. A., Li, J., Ansermino, J. M., Pipkin, F. B., Côté, A., Douglas, M. J., Gruslin, A., Hutcheon, J. A., Joseph, K. S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61351-7 · Cited by 593
Aggressive versus expectant management of severe preeclampsia at 28 to 32 weeks’ gestation: a randomized controlled trial
Sibai, B. M., Mercer, B. M., Schiff, E., & Friedman, S. A. (1994) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(94)90104-x · Cited by 458
An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia
Verlohren, S., Galindo, A., Schlembach, D., Zeisler, H., Herraı̀z, I., Moertl, M. G., Pape, J., Dudenhausen, J. W., Denk, B., & Stepan, H. (2009) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2009.09.016 · Cited by 433
Vitamins C and E to Prevent Complications of Pregnancy-Associated Hypertension
Roberts, J. M., Myatt, L., Spong, C. Y., Thom, E. A., Hauth, J. C., Leveno, K. J., Pearson, G. D., Wapner, R. J., Varner, M. W., Thorp, J. M., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908056 · Cited by 402
Hypertension in Pregnancy
Fisher, K. A., Luger, A., Spargo, B. H., & Lindheimer, M. D. (1981) · Medicine · doi:10.1097/00005792-198107000-00002 · Cited by 374
Prospective Study of Placental Angiogenic Factors and Maternal Vascular Function Before and After Preeclampsia and Gestational Hypertension
Noori, M., Donald, A. E., Angelakopoulou, A., Hingorani, A. D., & Williams, D. J. (2010) · Circulation · doi:10.1161/circulationaha.109.895458 · Cited by 364
Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia
Chaiworapongsa, T., Romero, R., Kim, Y. M., Kim, G. J., Kim, M. R., Espinoza, J., Bujold, E., Gonçalves, L., Gomez, R., Edwin, S., et al. (2005) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767050400028816 · Cited by 359
Pilot Study of Extracorporeal Removal of Soluble Fms-Like Tyrosine Kinase 1 in Preeclampsia
Thadhani, R., Kisner, T., Hagmann, H., Boßung, V., Noack, S., Schaarschmidt, W., Jank, A., Kribs, A., Cornely, O. A., Kreyssig, C., et al. (2011) · Circulation · doi:10.1161/circulationaha.111.034793 · Cited by 355
Diagnosis and management of atypical preeclampsia-eclampsia
Sibai, B. M., & Stella, C. L. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2008.07.048 · Cited by 353
Aggressive or expectant management for patients with severe preeclampsia between 28-34 weeks' gestation: a randomized controlled trial.
Odendaal, H. J., Pattinson, R., Bam, R. H., Grove, D., & Tj, K. (1990) · PubMed · Cited by 285
A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia
Kusanovic, J. P., Romero, R. J., Chaiworapongsa, T., Erez, O., Mittal, P., Vaisbuch, E., Mazaki‐Tovi, S., Gotsch, F., Edwin, S. S., Gómez, R., et al. (2009) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767050902994754 · Cited by 281
Recombinant Vascular Endothelial Growth Factor 121 Attenuates Hypertension and Improves Kidney Damage in a Rat Model of Preeclampsia
Li, Z., Zhang, Y., Jing, Y., Kapoun, A. M., Shao, Q., Kerr, I., Lam, A., O’Young, G., Sannajust, F. J., Stathis, P., et al. (2007) · Hypertension · doi:10.1161/hypertensionaha.107.092098 · Cited by 263
The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice
Lu, F., Longo, M., Tamayo, E. H., Maner, W. L., Al-Hendy, A. A., Anderson, G. D., Hankins, G. D. V., & Saade, G. R. (2007) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2006.12.024 · Cited by 229
VEGF and TGF-β are required for the maintenance of the choroid plexus and ependyma
Maharaj, A. S. R., Walshe, T. E., Saint‐Geniez, M., Venkatesha, S., Maldonado, A. E., Himes, N. C., Matharu, K., Karumanchi, S. A., & D'Amore, P. A. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072041 · Cited by 193
Neonatal outcome after preterm delivery for preeclampsia
Friedman, S. A., Schiff, E., Kao, L., & Sibai, B. M. (1995) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(95)91412-9 · Cited by 182
Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study
Sunderji, S., Gaziano, E. P., Wothe, D. D., Rogers, L. C., Sibai, B. M., Karumanchi, S. A., & Hodges-Savola, C. A. (2009) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2009.07.025 · Cited by 132
Can antenatal clinical and biochemical markers predict the development of severe preeclampsia?
Stamilio, D. M., Sehdev, H. M., Morgan, M. A., PROPERT, K. J., & Macones, G. A. (2000) · American Journal of Obstetrics and Gynecology · doi:10.1067/mob.2000.103890 · Cited by 128
New insights into the etiology of preeclampsia: identification of key elusive factors for the vascular complications
Ahmed, A. (2011) · Thrombosis Research · doi:10.1016/s0049-3848(11)70020-2 · Cited by 127
Current CHS and NHBPEP Criteria for Severe Preeclampsia Do Not Uniformly Predict Adverse Maternal or Perinatal Outcomes
Menzies, J., Magee, L. A., MacNab, Y. C., Ansermino, J. M., Li, J., Douglas, M. J., Gruslin, A., Kyle, P. M., Lee, S. K., Moore, M. P., et al. (2007) · Hypertension in Pregnancy · doi:10.1080/10641950701521742 · Cited by 114
Preterm Premature Rupture of the Membranes
Mercer, B. M. (2003) · Obstetrics and Gynecology · doi:10.1097/00006250-200301000-00033 · Cited by 109
Prediction of maternal complications and adverse infant outcome at admission for temporizing management of early-onset severe hypertensive disorders of pregnancy
Ganzevoort, W., Rep, A., de Vries, J. I. P., Bonsel, G. J., & Wolf, H. (2006) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2006.02.012 · Cited by 107
Preterm Premature Rupture of the Membranes
Mercer, B. M. (2008) · The Global Library of Women s Medicine · doi:10.3843/glowm.10120 · Cited by 72
The Role of Serum Uric Acid as a Prognostic Indicator of the Severity of Maternal and Fetal Complications in Hypertensive Pregnancies
Williams, K. P., & Galerneau, F. (2002) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(16)30193-1 · Cited by 63
Prediction of Adverse Maternal Outcomes in Preeclampsia
von Dadelszen, P., Payne, B. A., Li, J., Ansermino, J. M., Pipkin, F. B., Côté, A., Douglas, M. J., Gruslin, A., Hutcheon, J. A., Joseph, K. S., et al. (2012) · Obstetric Anesthesia Digest · doi:10.1097/01.aoa.0000410808.61878.a4 · Cited by 36
Prognostic Role of Uterine Artery Doppler in Patients with Preeclampsia
Meler, E., Figueras, F., Mula, R., Crispi, F., Benassar, M., Gómez, O., & Gratacós, E. (2009) · Fetal Diagnosis and Therapy · doi:10.1159/000258048 · Cited by 34
Technical performance of the first fully automated assays for human soluble fms-like tyrosine kinase 1 and human placental growth factor
Schneider, E., Gleixner, A., Hänel, R., Leyhe, Y., Kleinschmidt, C. K., Beck, G., Steinberg, M., Denk, B., & Gassner, D. (2009) · Zeitschrift für Geburtshilfe und Neonatologie · doi:10.1055/s-0029-1216308 · Cited by 15

Flagged first, then by citations

1 of the 39 references couldn’t be matched to a known paper.

Sorted by citations

Untitled work
Rana (2019) · doi:10.1161/circresaha.118.313276 · Cited by 2,095
Hypertensive Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management Recommendations for International Practice
Brown, M. A., Magee, L. A., Kenny, L. C., Karumanchi, S. A., McCarthy, F. P., Saito, S., Hall, D. R., Warren, C. E., Adoyi, G., & Ishaku, S. (2018) · Hypertension · doi:10.1161/hypertensionaha.117.10803 · Cited by 2,089
“Measurement of angiogenic factors may play a role in this regard in the future but is still at a research stage.(56)”
BackgroundSelf-citation
Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia
Zeisler, H., Llurba, E., Chantraine, F., Vatish, M., Staff, A. C., Sennström, M., Olovsson, M., Brennecke, S. P., Stepan, H., Allegranza, D., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1414838 · Cited by 1,872
Pre-eclampsia
Mol, B. W., Roberts, C. T., Thangaratinam, S., Magee, L. A., de Groot, C. J. M., & Hofmeyr, G. J. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00070-7 · Cited by 1,667
The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP
Tranquilli, A. L., Dekker, G., Magee, L. A., Roberts, J. M., Sibai, B. M., Steyn, W., Zeeman, G. G., & Brown, M. A. (2014) · Pregnancy Hypertension · doi:10.1016/j.preghy.2014.02.001 · Cited by 1,419

See all 668

Authors: Rana, S., Powe, C. E., Salahuddin, S., Verlohren, S., Perschel, F. H., Levine, R. J., Lim, K.-H., Wenger, J. B., Thadhani, R., & Karumanchi, S. A.
Affiliations: National Institutes of Health (US)
ORCID: Rana, Sarosh
Powe, Camille E.
Verlohren, Stefan
Perschel, Frank H.
Wenger, Julia B.
Thadhani, Ravi
Karumanchi, S. Ananth
Venue: Circulation
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2012-02-21
Volume: 125
Issue: 7
Pages: 911-919
ISSN: 0009-7322 (ISSN-L)
1524-4539
DOI: 10.1161/circulationaha.111.054361
PMC: PMC3319742
OpenAlex: W2134502189
Cited by: 668
References: 39
Citations by year: 2026: 30 · 2025: 51 · 2024: 40 · 2023: 46 · 2022: 50 · 2021: 52 · 2020: 49 · 2019: 48 · 2018: 49 · 2017: 48 · 2016: 49 · 2015: 42 · 2014: 49 · 2013: 41 · 2012: 20
FWCI: 58.66
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Circulation (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: Howard Hughes Medical Institute
Topics: Health Sciences › Medicine › Obstetrics and Gynecology › Pregnancy and preeclampsia studies
Health Sciences › Medicine › Clinical Neurology › Neurological Complications and Syndromes
Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Neonatal and fetal brain pathology
Keywords: preeclampsia, angiogenic factors, soluble fms-like tyrosine kinase-1, placental growth factor, sFlt-1/PlGF ratio, adverse maternal outcomes, perinatal outcomes, early-onset preeclampsia, proteinuria, hypertension, adverse outcome prediction, preterm birth, placental insufficiency, endothelial dysfunction, maternal morbidity
MeSH terms: Placenta Growth Factor, Adult, Female, Humans, Pre-Eclampsia, Pregnancy, Pregnancy Proteins, Prospective Studies, Risk, ROC Curve, Systole, Logistic Models, Vascular Endothelial Growth Factor Receptor-1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Angiogenic Factors and the Risk of Adverse Outcomes in Women With Suspected Preeclampsia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks